Browse studies

Find your next paid study

42 recruiting studies matching your filters

A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the…

Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder NeoplasmsCarcinoma in Situ

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06833073

Phase 2

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an ear…

Ductal Carcinoma in Situ

Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT06075953

Phase 3

A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/…

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Estimated

~$10 – $8,750

Ferring PharmaceuticalsNCT06545955

Phase 1

A Phase I/Ib Study Evaluating Intralesional TLR7 Agonist, CAN1012, in Pre-malignant Ductal Carcinoma in Situ and Lobular Carcinoma in Situ

This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.

Ductal Carcinoma in SituLobular Carcinoma in Situ

Estimated

~$10 – $7,500

Providence Health & ServicesNCT07408856

Observational

Accelerated Partial Breast Radiotherapy Study of a Personalized Holder for Prone Breast Immobilization to Enhance Local Delivery

The goal of this clinical trial is to find out whether using a personalized breast holder (called VENUS SHELL™) can improve positioning and patient comfort dur…

Invasive Breast Cancer Early StagesDuctal Carcinoma In Situ, DCIS

Estimated

~$10 – $7,500

HeroSupport SANCT07711847

Observational

Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer (Wisdom Study)

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics…

Breast Cancer ScreeningBreast Carcinoma in SituBreast Cancer

Estimated

~$10 – $5,625

University of California, San FranciscoNCT02620852

Observational

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions

This study will investigate a novel approach to marking surgical cavity margins following tumor resection, to allow for more accurate radiotherapy following on…

Ductal Carcinoma in SituBreast Cancer

Estimated

~$10 – $6,250

University of FloridaNCT06903468

Phase 2

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

This study evaluates the rates of radiation-specific toxicity, quality of life, and oncologic outcomes for early-stage breast cancer and ductal carcinoma in si…

Breast CancerEarly-stage Breast CancerDuctal Carcinoma in Situ+1 more

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT06902311

Phase 2

Phase II Basket Trial of Intraperitoneal Paclitaxel Plus Systemic Therapy in Gastrointestinal Malignancies With Peritoneal Carcinomatosis (STOPGAP - B)

This is a phase II open-label, basket clinical trial to assess the feasibility of systemic and Intraperitoneal chemotherapy in subjects with Gastrointestinal M…

Esophageal CarcinomaGastric Cancer (Diagnosis)Colorectal Adenocarcinoma+3 more

Estimated

~$10 – $6,250

University of California, IrvineNCT07795749

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patien…

Adrenal Gland PheochromocytomaCarcinoma In SituCentral Nervous System Neoplasm+15 more

Estimated

~$10 – $1,125

Children's Oncology GroupNCT02402244

Phase 3

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer

The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or …

Bladder (Urothelial, Transitional Cell) CancerNon-Muscle Invasive Bladder CarcinomaNon-muscle Invasive Bladder Cancer With Carcinoma in Situ

Estimated

~$10 – $8,750

Protara TherapeuticsNCT07480356

Phase 1

A Clinical Study of a Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Women with biopsy-proven ductal carcinoma in situ (DCIS) will be enrolled into two cohorts. One cohort will receive neoadjuvant therapy with an aromatase inhib…

Ductal Carcinoma in Situ

Estimated

~$10 – $7,500

Finn, Olivera, PhDNCT06218303